Deborah Hill Joins Satuit Technologies’ Board
BRAINTREE, Mass.--(BUSINESS WIRE)-- Satuit Technologies, Inc., a global leader in software solutions for the professional investment market is pleased to announce that Deborah Hill has joined its Board of Directors.
Deborah has a long career working with alternative asset management and software. She is currently with Solovis, a multi-asset class portfolio management software company where she’s Senior Vice President responsible for Account Management, Product Management and internal operations. Before Solovis, Deborah was Managing Director at Backstop Solutions Group. Prior to joining Backstop Solutions, Deborah was Global Practice Director with Kronos and Vice President of Consulting Resources with PeopleSoft.
Deborah holds a BA in Economic Theory from Wheaton College, an MBA from the Lake Forest Graduate School of Management and a certificate in International Business from Cambridge University.
"Deborah’s knowledge of the alternative asset management technology is a tremendous asset for Satuit. We are excited to have her join our board as we continue to grow in the alternative asset segment”, said Karen Maguire, CEO of Satuit.
ABOUT SATUIT TECHNOLOGIES, INC.
Satuit Technologies, Inc. is the premier provider of cloud-based and On-Premise CRM software solutions for the Institutional, wealth management, private equity, hedge fund, real estate and property markets. Satuit has offices in the United States and the United Kingdom, and serves clients in more than thirty-five countries. For additional information, visit www.satuit.com.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150701005978/en/
Satuit Technologies
Janet Keefe
[email protected]
or
Frank
Camacho, 781-871-7788
[email protected]
Source: Satuit Technologies, Inc.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- E-2 Investor Visa Trends to Watch in 2027
- Ivonescimab Monotherapy Demonstrates a Statistically Significant & Clinically Meaningful Benefit Compared to Pembrolizumab Monotherapy in PD-L1-Positive Advanced NSCLC in Akeso’s HARMONi-2 Study
- Crypto Presale 2026: Apeing’s 16.75 Billion Total Supply, 40% Presale Allocation Explained Alongside 5 Major Cryptocurrencies
Create E-mail Alert Related Categories
Press ReleasesRelated Entities
Hedge FundsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share